Original Articles and Brief Reports

High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients – final analysis of a randomized, multicenter, phase III trial

Central European Leukemia Study Group (CELSG), Internal Medicine V, Hematology and Oncology, Medical University Innsbruck, Innsbruck, Austria;Internal Medicine I, Hematology and Medical Oncology; Krankenhaus Barmherzige Schwestern Linz, Linz, Austria
Central European Leukemia Study Group (CELSG), Internal Medicine V, Hematology and Oncology, Medical University Innsbruck, Innsbruck, Austria
CCRI Children's Cancer Research Institute/LabDia Labordiagnostik, Vienna, Austria
Department of Hematology, RC Radiation Medicine, Kiev, Ukraine
Institute of Blood Pathology and Transfusion Medicine, Lviv, Ukraine
Clinical Center of Serbia, Institut za Haematologiju, Belgrad, Serbia and Montenegro
Clinics of Internal, Family Medicine and Oncology, Medical Faculty, Vilnius University, Hospital Santariskiu Clinics, Vilnius, Lithuania
National Center of Hematology, Riga, Latvia
University Hospital for Active Treatment “St. George”, Plovdiv, Bulgaria
University Hospital for Active Treatment “St. Marina”, Varna, Bulgaria
Clinic for Hematology, National Clinical Center Skopje, Skopje, Macedonia
National Center of Hematology and Transfusiology, Sofia, Bulgaria
University Hospital for Active Treatment, Pleven, Bulgaria
Kaunas University Hospital, Kaunas, Lithuania
Alexandrovska University Hospital, Sofia, Bulgaria
Department of Medical Statistics, Informatics and Health Economics, Medical University Innsbruck
Novartis, Basel, Switzerland
Novartis, Nurnberg, Germany, Bonn, Germany
Central European Leukemia Study Group (CELSG), Internal Medicine V, Hematology and Oncology, Medical University Innsbruck, Innsbruck, Austria
Central European Leukemia Study Group (CELSG), Internal Medicine V, Hematology and Oncology, Medical University Innsbruck, Innsbruck, Austria;University Hospital Bonn, Department of Hematology/Oncology, Bonn, Germany
Vol. 97 No. 10 (2012): October, 2012 https://doi.org/10.3324/haematol.2011.060087